课题基金 / 基金详情

BASIS OF PAX3-FKHR ONCOGENESIS IN RHABDOMYOSARCOMA

BASIS OF PAX3-FKHR ONCOGENESIS IN RHABDOMYOSARCOMA
横纹肌肉瘤中 PAX3-FKHR 致癌的基础
批准号:
2896046
负责人:
CHIAYENG WANG
金额:
$11.18万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-07-15 至 2002-06-30

项目摘要

项目成果

CHIAYENG WANG的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自摘要。)的长远目标 拟议的研究是了解PAX 3-FKHR在肺泡巨噬细胞中的作用, 横纹肌肉瘤(ARMS),一种胎儿骨骼来源的肿瘤, 常见于儿童。 PAX 3-FKHR是t(2;13)ARMS相关的 染色体易位 这种嵌合转录因子含有 PAX 3 DNA结合结构域和(更强的)FKHR反式激活结构域。 初步研究表明,PAX 3-FKHR异常激活基因, 血小板衍生生长因子α受体(PDGFaR)。 这是第一 受PAX 3-FKHR特异性影响的细胞靶基因的实例 而不是PAX 3。 第一个具体目标是描述PAX 3-FKHR应答 PDGFaR基因侧翼的元件。 第二个目标是绘制蛋白质图谱 在PAX 3-FKHR中的一个或多个基序,使其能够激活PDGFaR基因。 的 第三个目的是检查PDGFaR功能如何有助于ARMS肿瘤细胞 增长 由于PDGF是一种有效的有丝分裂生长因子, 它的受体可能在细胞转化中起关键作用。
英文摘要
DESCRIPTION: (Adapted from the abstract.) The long range goal of the proposed research is to understand the role of PAX3-FKHR in alveolar rhabdomyosarcoma (ARMS), a tumor of fetal skeletal origin that is most common in children. PAX3-FKHR is a product of t(2;13) ARMS-associated chromosomal translocations. This chimeric transcription factor contains the PAX3 DNA binding domain and the (stronger) FKHR transactivation domain. Preliminary studies show that PAX3-FKHR aberantly activates the gene for the platelet derived growth factor alpha receptor (PDGFaR). This is the first example of a cellular target gene that is specifically affected by PAX3-FKHR and not PAX3. The first specific aim is to delineate the PAX3-FKHR response element that flanks the PDGFaR gene. The second aim is to map the protein motif(s) in PAX3-FKHR that enables it to activate the PDGFaR gene. The third aim is to examine how PDGFaR function contributes to ARMS tumor cell growth. Since PDGF is a potent mitotic growth factor, aberrant expression of its receptor is likely to play a crucial role in cell transformation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Basis of PAX3-FKHR oncogenesis in rhabdomyosarcoma
Basis of PAX3-FKHR oncogenesis in rhabdomyosarcoma
Basis of PAX3-FKHR oncogenesis in rhabdomyosarcoma
Basis of PAX3-FKHR oncogenesis in rhabdomyosarcoma
海外基金